MIR-145's REGULATORY ROLE IN BREAST CANCER PROGRESSION

Delayed diagnosis of breast cancer results in lower treatment success rates and lower survival rates. Every year millions of women are diagnosed with breast cancer and many of them die from this disease. However, the discovery of biomarkers that enable early diagnosis should increase the success of treatment processes and extend survival times. In recent years, studies have been carried out to use microRNAs as biomarkers in the early detection of breast cancer. Research shows that microRNAs can serve as potential biomarkers for the diagnosis and prognosis of breast cancer. In addition to ongoing research on the possible use of microRNAs as biomarkers for early breast cancer diagnosis, our study also analyzed the possible use of miR-145 as a biomarker in breast cancer. In our study, RNA samples were isolated from blood serum samples of 200 breast cancer patients and 100 people in the healthy control group, and the specific expression levels of miR-145 were determined using RT-qPCR technique. As a result of these analyses, it was found that miR-145 had lower expression levels in breast cancer patients than in healthy controls. After further investigation of the biomarker potential of miR-145 in a larger group of breast cancer patients, it will be used as a target biomarker for early breast cancer diagnosis.